Zacks Investment Research downgraded shares of CHARLES RVR LAB (CRL) from OUTPERFORM to NEUTRAL on November 13, 2014, with a target price of $67.50.
Charles River Laboratories is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. Charles River is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies and has been in this business for more than 50 years.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CHARLES RVR LAB (CRL),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment